Polish biotech company Proteon Pharmaceuticals S.A, a global leader in the development and commercialization of bacteriophages for industrial use in livestock farming in poultry, dairy and aquaculture, has been awarded 2,9 mln Euro by the European Regional Development Fund to design and implement products that reduce the need for antibiotics in the human food chain.
Proteon received the Best “Innovation in Aquaculture Award”, from His Excellency, Saeed Albahri Salem Alameri, and Hans van der Beek, Director General of the Abu Dhabi Agriculture and Food Safety Authority at the Global Forum for Innovations in Agriculture (GFIA) in Abu Dhabi. Tom Cook, VP. Global Business Development at Proteon Pharmaceuticals, accepted the award.
Proteon Founder and Board Member, Professor Jarosław Dastych, made a major presentation at the Bacteriophage Therapy Summit in Boston, USA. He spoke on the topic of ” Aquaculture: Challenges and Lessons of Product Development” The Bacteriophage Therapy Summit is the only meeting uniting large pharma, biotech companies, research institutions and technology experts to harness bacteriophage science and accelerate the clinical
Proteon Receives “2019 Animal Health Innovation Award” at the Animal Health Investment Europe Conference in London, UK.. COO and Board Member Matthew Tebeau accepted the award on Proteon’s behalf. Animal Health Investment Europe is dedicated to showcasing to investors the most innovative emerging animal health companies covering the companion, aquaculture and production animal space.
Proteon Pharmaceuticals COO Matthew Tebeau sat down with Christine Corrado from Proactive Investors at the 11th Annual BioTech Showcase in San Francisco.
The Poland-based biotech aims to reduce reliance on antibiotics by using naturally-occurring bacteriophages to prevent and treat infectious diseases.
Proteon Pharmaceuticals today announced an investment of 21 million Euro to accelerate commercialization of its products, which aim to reduce the reliance on antibiotics within aquaculture and livestock farming. Proteon Pharmaceuticals uses bacteriophages to reduce the need for antibiotics, improve on-farm performance and increase the sustainability of protein production.
Proteon Pharmaceuticals was an invited speaker at the 9th edition of the FIAAP Animal Nutrition conference held on March 27, 2018 in Bangkok, Thailand. This one-day international conference highlighted the latest innovations and research in animal feed ingredients and additives. The event was co-located with five additional conferences as part of VICTAM Asia 2018.
Proteon Pharmaceuticals S.A., a Polish biotechnology firm has signed an agreement with an international Investment Fund, the Aqua-Spark fund, which invests in sustainable aquaculture. Proteon Pharmaceuticals will use the funds to commercialize its products globally, develop production capacity and support the development of its bacteriophage-platform technology.
Proteon Pharmaceuticals presents its unique product BAFADOR® at the international bacteriophage conference in Tbilisi Proteon Pharmaceuticals participated in the international conference “Centennial Celebration of Bacteriophage Research”, held in Tbilisi, Georgia on June 26-29, 2017. Proteon Pharmaceuticals’ R&D Director, Dr Ewelina Wójcik, presented the results of Company’s research, which has led to development of a phage-based
In 2016 Proteon Pharmaceuticals awarded grants from Polish Center for Research & Development for Euro 3.2 m In 2016, Proteon Pharmaceuticals signed the agreements for the co-financing five research projects from the European Union for Euro 3.2 million. The projects are for research and development of new generation, innovative products, based on our unique phage-platform
